MCID: FTT001
MIFTS: 63

Fatty Liver Disease

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Fatty Liver Disease

MalaCards integrated aliases for Fatty Liver Disease:

Name: Fatty Liver Disease 12 43 15
Fatty Liver 75 44 72
Fatty Liver, Alcoholic 44 72
Alcoholic Fatty Liver 12 33
Fatty Change of Liver 12
Fatty Liver Alcoholic 55
Steatosis of Liver 12
Hepatic Lipidosis 12
Steatohepatitis 72

Classifications:



External Ids:

Disease Ontology 12 DOID:9452
ICD9CM 35 571.0
SNOMED-CT 68 50325005 5360002
ICD10 33 K70.0 K76.0
UMLS 72 C0015695 C0015696 C2711227

Summaries for Fatty Liver Disease

MedlinePlus : 43 What is fatty liver disease? Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Fatty liver disease is a condition in which fat builds up in your liver. There are two main types: Nonalcoholic fatty liver disease (NAFLD) Alcoholic fatty liver disease, also called alcoholic steatohepatitis What is nonalcoholic fatty liver disease (NAFLD)? NAFLD is a type of fatty liver disease that is not related to heavy alcohol use. There are two kinds: Simple fatty liver, in which you have fat in your liver but little or no inflammation or liver cell damage. Simple fatty liver typically does not get bad enough to cause liver damage or complications. Nonalcoholic steatohepatitis (NASH), in which you have inflammation and liver cell damage, as well as fat in your liver. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. NASH may lead to cirrhosis or liver cancer. What is alcoholic fatty liver disease? Alcoholic fatty liver disease is due to heavy alcohol use. Your liver breaks down most of the alcohol you drink, so it can be removed from your body. But the process of breaking it down can generate harmful substances. These substances can damage liver cells, promote inflammation, and weaken your body's natural defenses. The more alcohol that you drink, the more you damage your liver. Alcoholic fatty liver disease is the earliest stage of alcohol-related liver disease. The next stages are alcoholic hepatitis and cirrhosis. Who is at risk for fatty liver disease? Researchers do not know the cause of nonalcoholic fatty liver (NAFLD). They do know that it is more common in people who Have type 2 diabetes and prediabetes Have obesity Are middle aged or older (although children can also get it) Are Hispanic, followed by non-Hispanic whites. It is less common in African Americans. Have high levels of fats in the blood, such as cholesterol and triglycerides Have high blood pressure Take certain drugs, such as corticosteroids and some cancer drugs Have certain metabolic disorders, including metabolic syndrome Have rapid weight loss Have certain infections, such as hepatitis C Have been exposed to some toxins NAFLD affects about 25 percent of people in the world. As the rates of obesity, type 2 diabetes, and high cholesterol are rising in the United States, so is the rate of NAFLD. NAFLD is the most common chronic liver disorder in the United States. Alcoholic fatty liver disease only happens in people who are heavy drinkers, especially those who have been drinking for a long period of time. The risk is higher for heavy drinkers who are women, have obesity, or have certain genetic mutations. What are the symptoms of fatty liver disease? Both NAFLD and alcoholic fatty liver disease are usually silent diseases with few or no symptoms. If you do have symptoms, you may feel tired or have discomfort in the upper right side of your abdomen. How is fatty liver disease diagnosed? Because there are often no symptoms, it is not easy to find fatty liver disease. Your doctor may suspect that you have it if you get abnormal results on liver tests that you had for other reasons. To make a diagnosis, your doctor will use Your medical history A physical exam Various tests, including blood and imaging tests, and sometimes a biopsy As part of the medical history, your doctor will ask about your alcohol use, to find out whether fat in your liver is a sign of alcoholic fatty liver disease or nonalcoholic fatty liver (NAFLD). He or she will also ask which medicines you take, to try to determine whether a medicine is causing your NAFLD. During the physical exam, your doctor will examine your body and check your weight and height. Your doctor will look for signs of fatty liver disease, such as An enlarged liver Signs of cirrhosis, such as jaundice, a condition that causes your skin and whites of your eyes to turn yellow You will likely have blood tests, including liver function tests and blood count tests. In some cases you may also have imaging tests, like those that check for fat in the liver and the stiffness of your liver. Liver stiffness can mean fibrosis, which is scarring of the liver. In some cases you may also need a liver biopsy to confirm the diagnosis, and to check how bad the liver damage is. What are the treatments for fatty liver disease? Doctors recommend weight loss for nonalcoholic fatty liver. Weight loss can reduce fat in the liver, inflammation, and fibrosis. If your doctor thinks that a certain medicine is the cause of your NAFLD, you should stop taking that medicine. But check with your doctor before stopping the medicine. You may need to get off the medicine gradually, and you might need to switch to another medicine instead. There are no medicines that have been approved to treat NAFLD. Studies are investigating whether a certain diabetes medicine or Vitamin E can help, but more studies are needed. The most important part of treating alcohol-related fatty liver disease is to stop drinking alcohol. If you need help doing that, you may want to see a therapist or participate in an alcohol recovery program. There are also medicines that can help, either by reducing your cravings or making you feel sick if you drink alcohol. Both alcoholic fatty liver disease and one type of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) can lead to cirrhosis. Doctors can treat the health problems caused by cirrhosis with medicines, operations, and other medical procedures. If the cirrhosis leads to liver failure, you may need a liver transplant. What are some lifestyle changes that can help with fatty liver disease? If you have any of the types of fatty liver disease, there are some lifestyle changes that can help: Eat a healthy diet, limiting salt and sugar, plus eating lots of fruits, vegetables, and whole grains Get vaccinations for hepatitis A and B, the flu and pneumococcal disease. If you get hepatitis A or B along with fatty liver, it is more likely to lead to liver failure. People with chronic liver disease are more likely to get infections, so the other two vaccinations are also important. Get regular exercise, which can help you lose weight and reduce fat in the liver Talk with your doctor before using dietary supplements, such as vitamins, or any complementary or alternative medicines or medical practices. Some herbal remedies can damage your liver.

MalaCards based summary : Fatty Liver Disease, also known as fatty liver, is related to fatty liver disease, nonalcoholic 1 and liver disease. An important gene associated with Fatty Liver Disease is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Developmental Biology and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Milk thistle and Losartan have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are homeostasis/metabolism and adipose tissue

Disease Ontology : 12 A lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in liver cells via the process of steatosis.

Wikipedia : 75 Fatty liver disease (FLD), also known as hepatic steatosis, is a condition where excess fat builds up in... more...

Related Diseases for Fatty Liver Disease

Diseases related to Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 690)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease, nonalcoholic 1 35.3 SREBF1 PPARA LEP INS ADIPOQ
2 liver disease 33.1 TNF PPARA PNPLA3 LEPR LEP INS
3 lipid metabolism disorder 32.7 PPARA LEP INS ADIPOQ
4 atherosclerosis susceptibility 32.0 TNF PPARA INS IL6 ADIPOQ
5 glucose intolerance 31.8 LEPR LEP IRS1 INS ADIPOQ
6 liver cirrhosis 31.8 MALAT1 LEP CYP2E1 ADIPOQ
7 vascular disease 31.7 TNF INS IL6 ADIPOQ
8 acanthosis nigricans 31.6 LEP INS ADIPOQ
9 alcoholic hepatitis 31.5 TNF IL6 CYP2E1
10 end stage renal failure 31.4 TNF LEP IL6
11 cerebrovascular disease 31.4 TNF INS IL6 ADIPOQ
12 abdominal obesity-metabolic syndrome 1 31.4 LEP INS ADIPOQ
13 periodontitis 31.4 TNF IL6 IL1B
14 arteries, anomalies of 31.4 TNF LEP INS IL6 IL1B ADIPOQ
15 arteriosclerosis 31.4 PPARA INS IL6 ADIPOQ
16 sleep disorder 31.4 LEP INS IL6
17 hyperglycemia 31.3 MALAT1 LEP IRS1 INS ADIPOQ
18 sleep apnea 31.3 TNF LEPR LEP INS IL6 IL1B
19 severe pre-eclampsia 31.3 LEPR LEP ADIPOQ
20 apnea, obstructive sleep 31.2 TNF LEP INS IL6 ADIPOQ
21 proteasome-associated autoinflammatory syndrome 1 31.1 TNF PPARA INS IL6 IL1B ADIPOQ
22 endometritis 31.0 TNF IL6 IL1B
23 autoimmune disease 31.0 TNF INS IL6 IL1B
24 prediabetes syndrome 31.0 LEP INS IL6 ADIPOQ
25 pancreas disease 31.0 TNF LEP INS IL6
26 protein-energy malnutrition 31.0 TNF LEP IL6
27 insulin-like growth factor i 31.0 LEP IRS2 IRS1 INS
28 lipid storage disease 30.9 SREBF1 PNPLA3 INS ADIPOQ
29 inherited metabolic disorder 30.8 SREBF1 PNPLA3 LEP INS ADIPOQ
30 intestinal disease 30.8 TNF IL6 IL1B
31 gastroenteritis 30.8 TNF IL6 IL1B
32 prader-willi syndrome 30.8 LEPR LEP INS ADIPOQ
33 acute respiratory distress syndrome 30.8 TNF IL6 IL1B
34 gestational diabetes 30.8 LEP IRS2 IRS1 INS ADIPOR1 ADIPOQ
35 peripheral nervous system disease 30.7 TNF INS IL6
36 eating disorder 30.7 LEPR LEP ADIPOQ
37 3-hydroxyacyl-coa dehydrogenase deficiency 30.6 PPARA LEP INS ADIPOQ
38 pre-eclampsia 30.6 MALAT1 LEP IL6 ADIPOQ
39 overnutrition 30.6 TNF SREBF1 PPARA LEPR LEP IRS1
40 large intestine cancer 30.5 TNF MAPK8 INS IL6 IL1B ADIPOQ
41 gastrointestinal system disease 30.5 TNF INS IL6 IL1B
42 duodenal ulcer 30.5 TNF INS IL1B
43 pyelonephritis 30.5 TNF IL6 IL1B
44 peritonitis 30.5 TNF IL6 IL1B
45 acquired immunodeficiency syndrome 30.5 TNF IL6 IL1B
46 toxic shock syndrome 30.4 TNF IL6 IL1B
47 pertussis 30.2 TNF IL6 IL1B
48 myocardial infarction 29.8 TNF INS IL6 IL1B ADIPOQ
49 diabetes mellitus, noninsulin-dependent 29.7 TNF SREBF1 PPARA MAPK8 LEPR LEP
50 acquired metabolic disease 29.5 TNF SREBF1 PPARA LEPR LEP IRS1

Comorbidity relations with Fatty Liver Disease via Phenotypic Disease Network (PDN):


Alcoholic Hepatitis Alcoholic Liver Cirrhosis

Graphical network of the top 20 diseases related to Fatty Liver Disease:



Diseases related to Fatty Liver Disease

Symptoms & Phenotypes for Fatty Liver Disease

MGI Mouse Phenotypes related to Fatty Liver Disease:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.49 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL1B IL6
2 adipose tissue MP:0005375 10.43 ADIPOQ ADIPOR1 ADIPOR2 IL6 INS IRS1
3 cardiovascular system MP:0005385 10.41 ADIPOQ CYP2E1 IL1B IL6 INS IRS1
4 liver/biliary system MP:0005370 10.41 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL6 INS
5 cellular MP:0005384 10.4 ADIPOQ ADIPOR1 ADIPOR2 IL6 INS IRS1
6 behavior/neurological MP:0005386 10.39 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL6 INS
7 growth/size/body region MP:0005378 10.38 ADIPOQ ADIPOR1 ADIPOR2 IL1B IL6 INS
8 mortality/aging MP:0010768 10.34 ADIPOQ CYP2E1 IL1B IL6 INS IRS1
9 endocrine/exocrine gland MP:0005379 10.33 ADIPOQ ADIPOR2 IL6 INS IRS1 IRS2
10 immune system MP:0005387 10.31 ADIPOQ IL1B IL6 INS IRS1 IRS2
11 hematopoietic system MP:0005397 10.26 ADIPOQ IL1B IL6 INS IRS1 LEP
12 integument MP:0010771 10.22 ADIPOQ IL1B IL6 INS IRS2 LEP
13 muscle MP:0005369 10.22 ADIPOQ ADIPOR1 IL6 INS IRS1 IRS2
14 nervous system MP:0003631 10.1 ADIPOQ ADIPOR2 IL1B IL6 INS IRS2
15 neoplasm MP:0002006 9.97 ADIPOQ CYP2E1 IL1B IL6 LEP LEPR
16 reproductive system MP:0005389 9.81 ADIPOR2 IL6 INS IRS2 LEP LEPR
17 renal/urinary system MP:0005367 9.8 ADIPOQ IL6 INS IRS2 LEP LEPR
18 skeleton MP:0005390 9.7 ADIPOQ ADIPOR1 ADIPOR2 IL1B IL6 INS
19 vision/eye MP:0005391 9.23 ADIPOR1 IL6 INS LEP LEPR MAPK8

Drugs & Therapeutics for Fatty Liver Disease

Drugs for Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 445)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
2
Losartan Approved Phase 4 114798-26-4 3961
3
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
4
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
5
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
6
Glucagon Approved Phase 4 16941-32-5
7
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
8
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
9
Liraglutide Approved Phase 4 204656-20-2 44147092
10
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
11
Insulin Detemir Approved Phase 4 169148-63-4 5311023
12
Insulin Aspart Approved Phase 4 116094-23-6 16132418
13
Gliclazide Approved Phase 4 21187-98-4 3475
14
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
15
Propranolol Approved, Investigational Phase 4 525-66-6 4946
16
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
17
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
18
Ribavirin Approved Phase 4 36791-04-5 37542
19
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
20
Tamoxifen Approved Phase 4 10540-29-1 2733526
21
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
22
Ergotamine Approved Phase 4 113-15-5 8223
23
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
24
Nortriptyline Approved Phase 4 72-69-5 4543
25
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
26
Glimepiride Approved Phase 4 93479-97-1 3476
27
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
28
Phentermine Approved, Illicit Phase 4 122-09-8 4771
29
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
30
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
31
Empagliflozin Approved Phase 4 864070-44-0
32
Alogliptin Approved Phase 4 850649-61-5 11450633
33
Testosterone enanthate Approved Phase 4 315-37-7 9416
34
Methyltestosterone Approved Phase 4 58-18-4 6010
35
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
36
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
37
Dulaglutide Approved, Investigational Phase 4 923950-08-7
38
Metformin Approved Phase 4 657-24-9 4091 14219
39
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
40
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
41
Insulin glargine Approved Phase 4 160337-95-1
42
Zinc Approved, Investigational Phase 4 7440-66-6 32051
43
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
44
Saxagliptin Approved Phase 4 361442-04-8 11243969
45
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
46
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
47
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
48
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
49
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
50
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 1095)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
3 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
4 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
5 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
6 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
7 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
8 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
9 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
10 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
11 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
12 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
13 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
14 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
15 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
16 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
17 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
18 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
19 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
20 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
21 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
22 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
23 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
24 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
25 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
26 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
27 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
28 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
29 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
30 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
31 Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus Completed NCT01951651 Phase 4 Exenatide;Glipizide
32 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
33 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
34 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
35 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
36 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
37 Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus Completed NCT01432405 Phase 4 Exenatide;Pioglitazone
38 Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome Completed NCT01356394 Phase 4
39 Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (SELLIFA). Randomized Controlled Trial Comparing the Tolerance on Lipids and Safety of Isocaloric Parenteral Nutrition With Enteral Nutrition. Completed NCT00522730 Phase 4
40 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
41 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
42 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
43 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
44 Mechanism of Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
45 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
46 A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
47 Cupping Therapy and SERKANGABIN Versus Conventional Treatment of Migraine Headache: a Randomized Controlled Trial Completed NCT01476930 Phase 4 conventional migraine drug treatment
48 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
49 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
50 Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Completed NCT01155206 Phase 4 glucagon

Search NIH Clinical Center for Fatty Liver Disease

Cochrane evidence based reviews: fatty liver

Genetic Tests for Fatty Liver Disease

Anatomical Context for Fatty Liver Disease

MalaCards organs/tissues related to Fatty Liver Disease:

41
Liver, Testes, Kidney, Heart, Endothelial, Ovary, Bone

Publications for Fatty Liver Disease

Articles related to Fatty Liver Disease:

(show top 50) (show all 24516)
# Title Authors PMID Year
1
Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease. 38 17
31393374 2019
2
Association between red cell distribution width-to-platelet ratio and hepatic fibrosis in nonalcoholic fatty liver disease: A cross-sectional study. 38 17
31348282 2019
3
The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease: An observational Study. 38 17
31277096 2019
4
Adiponectin: a key adipokine in alcoholic fatty liver. 9 38
19491377 2009
5
The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease. 9 38
19561788 2009
6
Molecular mechanisms of alcoholic fatty liver. 9 38
19032584 2009
7
Adiponectin and alcoholic fatty liver disease. 9 38
18709650 2008
8
Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? 9 38
16116627 2005
9
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. 9 38
16108051 2005
10
Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium. 9 38
15670659 2004
11
Clinical features and risk factors of patients with fatty liver in Guangzhou area. 9 38
15040041 2004
12
Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver. 9 38
14606109 2003
13
Elucidating the role of Lkb1 and mTOR in adipose tissue. 38
30318987 2019
14
PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. 38
31062641 2019
15
SWELL signalling in adipocytes: can fat 'feel' fat? 38
31112068 2019
16
Adipocytes as lipid sensors of oleic acid transport through a functional Caco-2/HT29-MTX intestinal barrier. 38
30905315 2019
17
Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat. 38
30757944 2019
18
Long non-coding RNA NEAT1 promotes steatosis via enhancement of estrogen receptor alpha-mediated AQP7 expression in HepG2 cells. 38
31062612 2019
19
S100A16, a novel lipogenesis promoting factor in livers of mice and hepatocytes in vitro. 38
31069793 2019
20
Exploring the protective effect of ShengMai-Yin and Ganmaidazao decoction combination against type 2 diabetes mellitus with nonalcoholic fatty liver disease by network pharmacology and validation in KKAy mice. 38
31216433 2019
21
Studies of the mechanism of fatty liver formation in Takifugu fasciatus following copper exposure. 38
31207574 2019
22
Creatine supplementation exacerbates ethanol-induced hepatic damage in mice. 38
31265967 2019
23
RNase MCPIP1 regulates hepatic peroxisome proliferator-activated receptor gamma via TXNIP/PGC-1alpha pathway. 38
31185306 2019
24
Endoplasmic reticulum stress: A master regulator of metabolic syndrome. 38
31325433 2019
25
Turnover of bile acids in liver, serum and caecal content by high-fat diet feeding affects hepatic steatosis in rats. 38
31170503 2019
26
Mechanisms of Environmental Contributions to Fatty Liver Disease. 38
31134516 2019
27
Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. 38
31145929 2019
28
Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis. 38
31195117 2019
29
Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. 38
30888971 2019
30
Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study. 38
31252266 2019
31
Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease. 38
30888972 2019
32
The association between lecithin-cholesterol acyltransferase activity and fatty liver index. 38
31084205 2019
33
Circulating levels of lipocalin-2 are associated with fatty pancreas but not fatty liver. 38
31276730 2019
34
Low-protein diet enhances adiponectin secretion in rats. 38
31130066 2019
35
Alkaloids of dendrobium nobile lindl. Altered hepatic lipid homeostasis via regulation of bile acids. 38
31132462 2019
36
Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes. 38
30847862 2019
37
Gut microbiome and microbial metabolites: a new system affecting metabolic disorders. 38
30788772 2019
38
Application of a layered model for determination of the elasticity of biological systems. 38
31252332 2019
39
Ascorbic acid attenuates cell stress by activating the fibroblast growth factor 21/fibroblast growth factor receptor 2/adiponectin pathway in HepG2 cells. 38
31322211 2019
40
Biomechanics of cultured hepatic cells during different steatogenic hits. 38
31151002 2019
41
Role and effective therapeutic target of gut microbiota in NAFLD/NASH. 38
31410156 2019
42
(5R)-5-hydroxytriptolide ameliorates liver lipid accumulation by suppressing lipid synthesis and promoting lipid oxidation in mice. 38
31301418 2019
43
High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. 38
30919112 2019
44
Mitochondrial dysfunction in high-fat diet-induced nonalcoholic fatty liver disease: The alleviating effect and its mechanism of Polygonatum kingianum. 38
31387169 2019
45
The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression. 38
30778201 2019
46
Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD). 38
31176163 2019
47
Microbiota and nonalcoholic fatty liver disease: promising prospects for clinical interventions? 38
31219825 2019
48
Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial. 38
31168845 2019
49
Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. 38
31353974 2019
50
Psychotropic Medications Are Associated With Increased Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver Disease. 38
31124886 2019

Variations for Fatty Liver Disease

Expression for Fatty Liver Disease

Search GEO for disease gene expression data for Fatty Liver Disease.

Pathways for Fatty Liver Disease

Pathways related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.51 TNF SREBF1 PPARA LEP IRS2 IRS1
2
Show member pathways
12.83 XBP1 TNF SREBF1 PPARA NR1H3 MLXIPL
3
Show member pathways
12.73 TNF LEP IRS2 IRS1 INS IL6
4
Show member pathways
12.59 TNF MAPK8 IRS2 IL6 IL1B
5
Show member pathways
12.56 TNF MAPK8 IL6 IL1B
6 12.53 SREBF1 IRS2 IRS1 INS ADIPOQ
7
Show member pathways
12.49 XBP1 SREBF1 NR1H3 MLXIPL MAPK8 IRS2
8
Show member pathways
12.47 MAPK8 LEPR LEP IRS2 IRS1 INS
9
Show member pathways
12.43 SREBF1 LEPR LEP IRS2 IRS1 INS
10 12.36 XBP1 TNF MAPK8 IL6
11
Show member pathways
12.34 TNF INS IL6 IL1B
12
Show member pathways
12.34 TNF MAPK8 IL6 IL1B
13
Show member pathways
12.34 MLXIPL INS ADIPOR2 ADIPOR1 ADIPOQ
14
Show member pathways
12.32 TNF MAPK8 IL6 IL1B
16
Show member pathways
12.28 TNF SREBF1 MAPK8 IRS1
17 12.24 TNF MAPK8 IL6 IL1B
18
Show member pathways
12.23 TNF MAPK8 IL6 IL1B
19
Show member pathways
12.21 TNF MAPK8 IL6 IL1B
20
Show member pathways
12.21 LEP IRS2 IRS1 INS
21
Show member pathways
12.15 IRS2 IRS1 INS ADIPOR2 ADIPOR1 ADIPOQ
22 12.06 MAPK8 IRS2 IRS1 INS
23
Show member pathways
12.06 MAPK8 IRS2 IRS1 INS IL6
24
Show member pathways
12 TNF SREBF1 PPARA NR1H3 MLXIPL MAPK8
25 11.99 TNF LEP IL6 IL1B
26 11.94 TNF MAPK8 IL6 IL1B
27
Show member pathways
11.89 TNF MAPK8 IRS2 IRS1 INS ADIPOQ
28 11.88 TNF MAPK8 IL6 IL1B
29 11.87 TNF IL6 IL1B
30 11.82 TNF SREBF1 PPARA PNPLA3 NR1H3 LEP
31 11.81 MAPK8 IL6 IL1B
32 11.77 PPARA NR1H3 ADIPOQ
33 11.76 TNF IL6 IL1B
34 11.74 TNF IL6 IL1B
35 11.74 TNF MAPK8 IL6 IL1B
36 11.7 MAPK8 IRS1 INS
37 11.69 TNF PPARA MAPK8 LEPR LEP IRS2
38
Show member pathways
11.68 TNF IL6 IL1B
39 11.67 TNF IL6 IL1B
40 11.61 TNF IL6 IL1B
41 11.6 MAPK8 INS IL6
42 11.6 IRS2 IRS1 INS
43 11.56 LEPR LEP IRS2 IRS1
44 11.55 TNF MAPK8 IL6
45 11.54 LEPR LEP IRS1 INS
46 11.53 TNF IL6 IL1B
47 11.53 TNF IL6 IL1B
48 11.49 TNF IL6 IL1B
49 11.41 MAPK8 IRS2 IRS1
50 11.37 SREBF1 MLXIPL IRS1

GO Terms for Fatty Liver Disease

Biological processes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TNF INS IL6 IL1B
2 lipid metabolic process GO:0006629 9.97 XBP1 SREBF1 PPARA PNPLA3 NR1H3 LEP
3 positive regulation of protein kinase B signaling GO:0051897 9.96 TNF LEP IRS2 IRS1 INS
4 regulation of lipid metabolic process GO:0019216 9.93 PPARA IRS2 ADIPOR1
5 insulin receptor signaling pathway GO:0008286 9.93 SREBF1 IRS2 IRS1 INS
6 circadian rhythm GO:0007623 9.92 SREBF1 LEP ADIPOQ
7 cholesterol metabolic process GO:0008203 9.92 SREBF1 LEPR LEP
8 response to nutrient GO:0007584 9.92 LEP ADIPOR2 ADIPOQ
9 response to glucose GO:0009749 9.91 SREBF1 IRS2 ADIPOQ
10 response to insulin GO:0032868 9.91 PPARA LEP IRS1
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.9 TNF LEP INS
12 positive regulation of T cell proliferation GO:0042102 9.89 LEP IL6 IL1B
13 positive regulation of interleukin-6 production GO:0032755 9.88 TNF IL6 IL1B
14 response to hypoxia GO:0001666 9.88 PPARA LEP ADIPOQ
15 regulation of insulin secretion GO:0050796 9.88 TNF SREBF1 LEP IL1B
16 hormone-mediated signaling pathway GO:0009755 9.87 PPARA ADIPOR2 ADIPOR1
17 regulation of circadian rhythm GO:0042752 9.87 PPARA NR1H3 MAPK8
18 negative regulation of fat cell differentiation GO:0045599 9.87 TNF IL6 ADIPOQ
19 intracellular receptor signaling pathway GO:0030522 9.85 SREBF1 PPARA NR1H3
20 positive regulation of cold-induced thermogenesis GO:0120162 9.85 LEPR LEP ADIPOR2 ADIPOR1 ADIPOQ
21 lipid homeostasis GO:0055088 9.84 PNPLA3 NR1H3 IRS2
22 response to ethanol GO:0045471 9.83 LEP CYP2E1 ADIPOQ
23 positive regulation of interleukin-8 production GO:0032757 9.83 TNF IL1B ADIPOQ
24 positive regulation of JAK-STAT cascade GO:0046427 9.83 LEP IL6 ADIPOR1
25 cellular response to insulin stimulus GO:0032869 9.83 XBP1 SREBF1 IRS2 IRS1 ADIPOQ
26 negative regulation of neurogenesis GO:0050768 9.81 TNF IL6 IL1B
27 positive regulation of glycogen biosynthetic process GO:0045725 9.8 IRS2 IRS1 INS
28 positive regulation of glial cell proliferation GO:0060252 9.8 TNF IL6 IL1B
29 cellular response to lipopolysaccharide GO:0071222 9.8 XBP1 TNF NR1H3 MAPK8 IL6 IL1B
30 positive regulation of cellular protein metabolic process GO:0032270 9.79 NR1H3 INS ADIPOQ
31 negative regulation of lipid catabolic process GO:0050995 9.79 TNF INS IL1B
32 fatty acid oxidation GO:0019395 9.77 ADIPOR2 ADIPOR1 ADIPOQ
33 fatty acid homeostasis GO:0055089 9.77 XBP1 MLXIPL INS
34 response to glucocorticoid GO:0051384 9.76 TNF IL6 ADIPOQ
35 positive regulation of fatty acid biosynthetic process GO:0045723 9.75 NR1H3 MLXIPL
36 regulation of protein secretion GO:0050708 9.75 TNF INS
37 positive regulation of triglyceride biosynthetic process GO:0010867 9.75 SREBF1 NR1H3
38 positive regulation of immunoglobulin secretion GO:0051024 9.74 XBP1 IL6
39 sexual reproduction GO:0019953 9.74 LEPR LEP
40 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.74 IL1B ADIPOQ
41 positive regulation of glucose metabolic process GO:0010907 9.74 IRS2 IRS1
42 negative regulation of gluconeogenesis GO:0045721 9.74 LEPR INS ADIPOQ
43 negative regulation of synaptic transmission GO:0050805 9.73 IL1B ADIPOQ
44 negative regulation of appetite GO:0032099 9.73 PPARA LEP
45 positive regulation of chemokine biosynthetic process GO:0045080 9.72 TNF IL1B
46 negative regulation of cholesterol storage GO:0010887 9.72 PPARA NR1H3
47 cellular response to glucose stimulus GO:0071333 9.72 XBP1 IRS2
48 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.72 PPARA NR1H3 ADIPOQ
49 regulation of establishment of endothelial barrier GO:1903140 9.71 TNF IL1B
50 interleukin-6 production GO:0032635 9.71 LEP IL1B

Molecular functions related to Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.83 XBP1 SREBF1 PPARA NR1H3 MLXIPL
2 signaling receptor activity GO:0038023 9.76 PPARA NR1H3 ADIPOR2 ADIPOR1
3 cytokine activity GO:0005125 9.71 TNF IL6 IL1B ADIPOQ
4 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.56 XBP1 SREBF1 PPARA NR1H3
5 nuclear receptor activity GO:0004879 9.54 SREBF1 PPARA NR1H3
6 adiponectin binding GO:0055100 9.32 ADIPOR2 ADIPOR1
7 sterol response element binding GO:0032810 9.16 SREBF1 NR1H3
8 adipokinetic hormone receptor activity GO:0097003 8.96 ADIPOR2 ADIPOR1
9 insulin receptor binding GO:0005158 8.8 IRS2 IRS1 INS

Sources for Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....